Are you Dr. Gralla?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 63 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
450 Lakeville Rd
New Hyde Park, NY 11042Phone+1 516-734-8900Fax+1 516-734-8934
Summary
- Dr. Richard Gralla, MD is an oncologist in New Hyde Park, New York. He is currently licensed to practice medicine in New York and Louisiana. He is affiliated with NYC Health + Hospitals / Jacobi and NYC Health + Hospitals / South Brooklyn Health.
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1974 - 1977
- Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Internal Medicine, 1972 - 1974
- University of Virginia School of MedicineClass of 1972
Certifications & Licensure
- NY State Medical License 1974 - 2025
- LA State Medical License 1990 - 2000
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 4 citations2020 ASCO, 2023 NCCN, 2023 MASCC/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer pati...Samantha K F Kennedy, Shannon Goodall, Shing Fung Lee, Carlo DeAngelis, Allison Jocko
Supportive Care in Cancer. 2024-04-10 - 8 citationsEmetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC/ESMO consensus recommendation.Karin Jordan, Alexandre Chan, Richard J Gralla, Franziska Jahn, Bernardo Rapoport
Supportive Care in Cancer. 2023-12-22 - 7 citations2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents.Florian Scotté, Lee Schwartzberg, Hirotoshi Iihara, Matti Aapro, Richard Gralla
Supportive Care in Cancer. 2023-12-20
Authored Content
- Evaluation of Health-Related Quality of Life and Symptoms in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Treated with Nivolumab or Docetaxel in CheckMate 057September 2018
Press Mentions
- 5 Key Takeaways from Mesothelioma Expert TeleconferenceApril 9th, 2018
- FDA Approves Rolapitant for CINVSeptember 2nd, 2015